Suppr超能文献

口服胞磷胆碱疗法对原发性开角型青光眼患者视网膜神经纤维层和神经节细胞-内丛状层的影响。

Effect of oral citicoline therapy on retinal nerve fiber layer and ganglion cell-inner plexiform layer in patients with primary open angle glaucoma.

作者信息

Sahin Asena Keles, Kapti Hasan Burhanettin, Uzun Aslihan

机构信息

Department of Ophthalmology, Training and Research Hospital, Ordu University, Ordu 52000, Turkey.

出版信息

Int J Ophthalmol. 2022 Mar 18;15(3):483-488. doi: 10.18240/ijo.2022.03.17. eCollection 2022.

Abstract

AIM

To evaluate the short-term effects of oral citicoline therapy on the retinal nerve fiber layer (RNFL) and the macular ganglion cell-inner plexiform layer (mGCIPL) in patients with primary open angle glaucoma (POAG).

METHODS

Fifty-four eyes of 54 patients with POAG glaucoma included in the study. In addition to a topical hypotensive, 250-mg oral citicoline was administered to 27 patients, while 27 patients were assigned as the control group. RNFL and mGCIPL values were measured using optical coherence tomography (OCT) at 1d before treatment and 3mo after the initiation of treatment. At the third month visit, citicoline treatment was discontinued and drug-free control (wash-out) measurements were obtained at the fourth month in citicoline group.

RESULTS

The average RNFL thickness was significantly higher at month 3 than the baseline (=0.038) in citicoline group. However, this improvement partially regressed after a 1-month wash-out period. No statistically significant changes in RNFL were observed in the superior, nasal, temporal and inferior quadrants at months 3 and 4 (>0.05). The change in the average and inferior quadrant RNFL thickness in the citicoline group at 3mo was significantly greater than the control group (=0.006 and =0.014, respectively). There were no significant differences between the groups according to the change in mGCIPL thickness and the superior, nasal and temporal quadrant RNFL thickness (>0.05).

CONCLUSION

With oral citicoline treatment, the loss in the average RNFL is prevented in POAG patients in the short-term. Study data show that citicoline may have a significant impact on slowing glaucoma progression, which could have a potential neuroprotective effect.

摘要

目的

评估口服胞磷胆碱治疗对原发性开角型青光眼(POAG)患者视网膜神经纤维层(RNFL)和黄斑神经节细胞 - 内丛状层(mGCIPL)的短期影响。

方法

本研究纳入54例POAG患者的54只眼。除局部使用降眼压药物外,27例患者口服250mg胞磷胆碱,另27例患者作为对照组。在治疗前1天和治疗开始后3个月使用光学相干断层扫描(OCT)测量RNFL和mGCIPL值。在第三个月随访时,停止胞磷胆碱治疗,并在第四个月对胞磷胆碱组进行停药后(洗脱期)测量。

结果

胞磷胆碱组在第3个月时平均RNFL厚度显著高于基线(=0.038)。然而,经过1个月的洗脱期后,这种改善部分消退。在第3个月和第4个月时,RNFL在上、鼻、颞和下象限均未观察到统计学上的显著变化(>0.05)。胞磷胆碱组在3个月时平均和下象限RNFL厚度的变化显著大于对照组(分别为=0.006和=0.014)。根据mGCIPL厚度变化以及上、鼻和颞象限RNFL厚度,两组之间无显著差异(>0.05)。

结论

口服胞磷胆碱治疗可在短期内防止POAG患者平均RNFL的丢失。研究数据表明,胞磷胆碱可能对延缓青光眼进展有显著影响,可能具有潜在的神经保护作用。

相似文献

3
Macular inner plexiform and retinal nerve fiber layer thickness in glaucoma.
Optom Vis Sci. 2014 Nov;91(11):1320-7. doi: 10.1097/OPX.0000000000000392.
4
Comparative analysis of mean retinal thickness measured using SD-OCT in normal young or old age and glaucomatous eyes.
Int Ophthalmol. 2018 Dec;38(6):2417-2426. doi: 10.1007/s10792-017-0744-7. Epub 2017 Oct 12.
5
Temporal Relation between Macular Ganglion Cell-Inner Plexiform Layer Loss and Peripapillary Retinal Nerve Fiber Layer Loss in Glaucoma.
Ophthalmology. 2017 Jul;124(7):1056-1064. doi: 10.1016/j.ophtha.2017.03.014. Epub 2017 Apr 10.
6
[The function-structure impairment pattern of optic nerves in primary open-angle glaucoma and normal-tension glaucoma].
Zhonghua Yan Ke Za Zhi. 2018 Nov 11;54(11):811-819. doi: 10.3760/cma.j.issn.0412-4081.2018.11.004.
9
Analysis of the retinal nerve fiber and ganglion cell - Inner plexiform layer by optical coherence tomography in Parkinson's patients.
Parkinsonism Relat Disord. 2016 Oct;31:59-64. doi: 10.1016/j.parkreldis.2016.07.004. Epub 2016 Jul 9.
10
Comparison of ganglion cell and retinal nerve fiber layer thickness in primary open-angle glaucoma and normal tension glaucoma with spectral-domain OCT.
Graefes Arch Clin Exp Ophthalmol. 2013 Mar;251(3):831-8. doi: 10.1007/s00417-012-2114-5. Epub 2012 Aug 18.

引用本文的文献

1
Next-Gen Neuroprotection in Glaucoma: Synergistic Molecules for Targeted Therapy.
J Clin Med. 2025 Aug 30;14(17):6145. doi: 10.3390/jcm14176145.
3
Neuroprotection beyond intraocular pressure: game changer or quiet addiction.
Graefes Arch Clin Exp Ophthalmol. 2025 Apr 5. doi: 10.1007/s00417-025-06816-7.
4
Neuroprotective Effect of the Combination of Citicoline and CoQ10 in a Mouse Model of Ocular Hypertension.
Antioxidants (Basel). 2024 Dec 24;14(1):4. doi: 10.3390/antiox14010004.
5
Efficacy of citicoline as a supplement in glaucoma patients: A systematic review.
PLoS One. 2023 Sep 28;18(9):e0291836. doi: 10.1371/journal.pone.0291836. eCollection 2023.
6
Restored retinal physiology after administration of niacin with citicoline in a mouse model of hypertensive glaucoma.
Front Med (Lausanne). 2023 Sep 5;10:1230941. doi: 10.3389/fmed.2023.1230941. eCollection 2023.
7
Combined use of coenzyme Q10 and citicoline: A new possibility for patients with glaucoma.
Front Med (Lausanne). 2022 Dec 15;9:1020993. doi: 10.3389/fmed.2022.1020993. eCollection 2022.
8
Citicoline: pharmacological and clinical review, 2022 update.
Rev Neurol. 2022 Nov 30;75(s05):S1-S89. doi: 10.33588/rn.75s05.2022311.

本文引用的文献

2
Protective effects of citicoline-containing eye drops against UVB-Induced corneal oxidative damage in a rat model.
Exp Eye Res. 2021 Jul;208:108612. doi: 10.1016/j.exer.2021.108612. Epub 2021 May 13.
3
Transneuronal Degeneration in the Brain During Glaucoma.
Front Aging Neurosci. 2021 Apr 6;13:643685. doi: 10.3389/fnagi.2021.643685. eCollection 2021.
4
Citicoline Modulates Glaucomatous Neurodegeneration Through Intraocular Pressure-Independent Control.
Neurotherapeutics. 2021 Apr;18(2):1339-1359. doi: 10.1007/s13311-021-01033-6. Epub 2021 Apr 13.
5
Citicoline as Adjuvant Therapy in Parkinson's Disease: A Systematic Review.
Clin Ther. 2021 Jan;43(1):e19-e31. doi: 10.1016/j.clinthera.2020.11.009. Epub 2020 Dec 3.
6
Innovative IOP-Independent Neuroprotection and Neuroregeneration Strategies in the Pipeline for Glaucoma.
J Ophthalmol. 2020 Apr 10;2020:9329310. doi: 10.1155/2020/9329310. eCollection 2020.
10
Neuroprotection in Glaucoma: Towards Clinical Trials and Precision Medicine.
Curr Eye Res. 2020 Mar;45(3):327-338. doi: 10.1080/02713683.2019.1663385. Epub 2019 Sep 16.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验